TAK-024 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor targeting specific pathways involved in cancer cell proliferation and survival. Research suggests that TAK-024 may be effective in treating certain types of tumors by disrupting key signaling mechanisms that promote cancer growth. Its application is being explored in preclinical and clinical studies to evaluate its efficacy and safety in cancer patients. Additionally, TAK-024 is being studied for its potential to enhance the effectiveness of other cancer treatments when used in combination therapies. These investigations aim to provide new options for patients with limited treatment alternatives.